Literature DB >> 12032023

The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat.

Gopi A Tejwani1, Anil K Rattan.   

Abstract

UNLABELLED: The intrathecal administration of morphine has been the standard therapy to control long-term intractable pain. Recently, a panel of pain therapy experts suggested that because of the lack of efficacy or because of the side effects produced by morphine in some patients, other drugs, such as hydromorphone and buprenorphine, should be investigated for their analgesic properties. We designed this study to compare the efficacy of intrathecal hydromorphone and buprenorphine to suppress thermal nociception in male Sprague-Dawley rats. An additional objective was to understand whether hydromorphone and buprenorphine bind and act as agonists to mu-, delta-, and kappa-spinal opioid receptors. Intrathecally-administered hydromorphone and buprenorphine produced a dose- and time-dependent increase in the tail-flick response latency in rats. The 50% effective dose value for the antinociceptive effect of buprenorphine and hydromorphone were 4 and 69.5 nmol/L, respectively. Both drugs act as agonists to mu-opioid receptors, as determined by their ability to displace [(3)H]-DAMGO from the spinal opioid receptors and by the ability of an opioid receptor antagonist, naloxone, to reverse their antinociceptive effects. Buprenorphine also has an agonistic effect on the kappa-opioid receptors. For the first time, we report that intrathecal buprenorphine is approximately 17 times more effective than hydromorphone in inhibiting thermal pain, and buprenorphine produces its antinociceptive effect by acting as an agonist at both mu- and kappa-spinal opioid receptors. Naloxone administered intrathecally was effective in preventing the antinociceptive effects of subsequent intrathecal injections of buprenorphine. IMPLICATIONS: Hydromorphone and buprenorphine are two important drugs used for pain relief. We observed that intrathecal buprenorphine is 17 times more potent than hydromorphone to inhibit pain in rats. Both drugs exert their effects through specific spinal opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032023     DOI: 10.1097/00000539-200206000-00031

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Authors:  Devki D Sukhtankar; Nurulain T Zaveri; Stephen M Husbands; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2013-05-07       Impact factor: 4.030

Review 2.  Buprenorphine-naloxone therapy in pain management.

Authors:  Kelly Yan Chen; Lucy Chen; Jianren Mao
Journal:  Anesthesiology       Date:  2014-05       Impact factor: 7.892

3.  Transdermal buprenorphine - a critical appraisal of its role in pain management.

Authors:  Guy Hans; Dominique Robert
Journal:  J Pain Res       Date:  2009-09-15       Impact factor: 3.133

Review 4.  A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.

Authors:  Jeffrey Gudin; Jeffrey Fudin
Journal:  Pain Ther       Date:  2020-01-28

5.  Multicenter Observational/Exploratory Study Addressed to the Evaluation of the Effectiveness and Safety of Pharmacological Therapy in Opioid-Dependent Patients in Maintenance Therapy in Southern Italy.

Authors:  Fatima Maqoud; Giada Fabio; Nunzio Ciliero; Marina Antonacci; Francesca Mastrangelo; Giorgio Sammarruco; Roberto Cataldini; Gabriella Schirosi; Salvatore De Fazio; Domenico Tricarico
Journal:  Pharmaceutics       Date:  2022-02-21       Impact factor: 6.321

6.  Fentanyl but Not Morphine or Buprenorphine Improves the Severity of Necrotizing Acute Pancreatitis in Rats.

Authors:  Emese Réka Bálint; Gabriella Fűr; Balázs Kui; Zsolt Balla; Eszter Sára Kormányos; Erik Márk Orján; Brigitta Tóth; Gyöngyi Horváth; Edina Szűcs; Sándor Benyhe; Eszter Ducza; Petra Pallagi; József Maléth; Viktória Venglovecz; Péter Hegyi; Lóránd Kiss; Zoltán Rakonczay
Journal:  Int J Mol Sci       Date:  2022-01-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.